Guggenheim Upgrades GlaxoSmithKline (GSK) to Buy, 'Vaccines, HIV, I&I, AND Oncology Set Up Improved 2024+ Growth'
Tweet Send to a Friend
Guggenheim analyst Seamus Fernandez upgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Buy.The analyst comments "We are upgrading GSK to BUY ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
